To evaluate the effectiveness and safety of ring augmentation of Roux-en-Y gastric bypass (RYGB) with a MiniMizer ring in patients with a BMI ≥ 50 kg/m2, addressing the need for effective surgical options in this high-risk group.
Key Findings:
Mean %TWL was 16% at 3 months, 25% at 6 months, 32.1% at 1 year, and 35% at 2 years, indicating progressive weight loss.
Median BMI decreased from 54 kg/m2 at baseline to 34.0 kg/m2 at 2 years, demonstrating significant weight reduction.
Significant reductions in diabetes mellitus (14% to 3%), hypertension (35% to 18%), and obstructive sleep apnea syndrome (21% to 9%) were observed, highlighting the procedure's impact on obesity-related comorbidities.
Interpretation:
The MiniMizer ring augmentation in raRYGB is effective in achieving significant weight loss and improving obesity-related comorbidities in patients with severe obesity.
Limitations:
Retrospective design may introduce bias, limiting the ability to establish causation.
Limited generalizability due to single-center study, which may not reflect broader patient populations.
Conclusion:
Ring augmentation with the MiniMizer ring in RYGB is a safe and effective option for patients with a BMI >50 kg/m2, leading to substantial weight loss and improvement in obesity-related conditions, suggesting its potential as a preferred surgical approach in this demographic.
